logo
Breaking News
Plus   Neg
Share
Email

KineMed And Pfizer Extend Collaboration On Type II Diabetes - Quick Facts

KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.

KineMed stated that the collaboration employs its novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

"This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials," said Marc Hellerstein, President, Chief Science Officer and Co-founder at KineMed.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Boeing Q1 Profit Surges, Revenues Up 6%; Increases FY18 Guidance
The Boeing Company (BA) reported that its first-quarter core earnings per share increased to $3.64 from $2.17, prior year, reflecting strong performance across the company. Core operating earnings improved 35% year-over-year to $2.51 billion from $1.86 billion, previous year. GAAP earnings from operations...
Twitter Q1 Results Beat Estimates; Shares Rise
Micro-blogging site Twitter Inc. on Wednesday reported a turnaround to profit in the first quarter on strong double-digit revenue growth. This is the company's second quarterly profit. Both revenue and adjusted earnings per share beat analysts' estimates. Twitter's average monthly active users or MAU figure rose 3 percent year-over-year and also increased from the preceding quarter.
Credit Suisse Stock Up On Higher Q1 Profit
Shares of Credit Suisse Group AG were gaining around 4 percent in Swiss trading after the banking giant reported Wednesday higher profit in its first quarter, despite lower net interest income. The company said it had planned 2018 to be a year of acceleration in its performance in its 12-quarter restructuring program.
Follow RTT
Copyright © 2018 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Feedback   |   Sitemap